<DOC>
	<DOC>NCT00207051</DOC>
	<brief_summary>This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.</brief_summary>
	<brief_title>BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Diagnosis of advanced or metastatic (tumor has spread) gastrointestinal malignancy Feeling well other than cancer diagnosis (ie lab work, no infection, etc) Available tumor tissue sample from prior surgery Measurable disease on scans 46 weeks since prior therapy and recovered from the effects of prior therapy Men and women, ages 18 and above Women must not be pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Advanced Gastrointestinal Malignancies</keyword>
</DOC>